AI Trailblazer Dr. Jia Li and Early Stage AI Venture Expert Shea Tate-Di Donna Join CerebraAI Advisory Board
23 Julio 2024 - 10:00AM
Business Wire
Dr. Jia Li, distinguished IEEE Fellow for
Leadership in Large Scale AI and Founding Head of R&D for
Google Cloud AI, brings unparalleled insights and expertise to
generative AI digital twin medical imaging
Shea Tate-Di Donna, career venture capitalist,
entrepreneur, and author, renowned for transforming strategic
visions into actionable results, brings early stage AI venture and
fundraising expertise dedicated to CerebraAI’s U.S. and global
market growth
CerebraAI, an AI-driven neuroradiology software company focused
on acute ischemic stroke detection, is honored to welcome AI
industry leader Dr. Jia Li and accomplished product creator,
operator, and investor Shea Tate-Di Donna to its Advisory Board.
Guiding CerebraAI’s R&D and fundraising pathways, Dr. Li and
Shea Tate-Di Donna join an esteemed group of advisors in their
respective fields to support CerebraAI in the process of developing
its brain imaging analysis map. With a novel approach of creating
personalized AI-generated images of the patient’s pseudo-healthy
brain to enhance non-contrast CT (NCCT) scans, the deep-learning AI
model is being developed for physicians to rapidly diagnose acute
ischemic stroke.
Dr. Jia Li’s pioneering accomplishments in AI span more than two
decades of industry-leading recognition. In addition to her
distinguished leadership as an IEEE Fellow, Founding Head of
R&D and Co-founder of Google Cloud AI, and previous roles
including Adjunct Professor and inaugural course instructor for
Generative AI in Medicine at Stanford University, she is
Co-founder, Chief AI Officer, and President of LiveX AI, empowering
businesses with a trusted AI Agent for unmatched customer
engagement across all platforms. With a dedicated passion for
making a positive impact in healthcare through generative AI, Jia
also co-founded and is Board Chair of HealthUnity, an open
consortium of data scientists, AI experts, and healthcare
visionaries building metrics and benchmarks to help guide the
industry.
“I first met CerebraAI as the Digital Health winner of our
HealthUnity Generative AI in Healthcare Startup Challenge at
Stanford in 2023,” stated Dr. Jia Li, Co-founder, Chief AI Officer,
and President of LiveX AI and Board Chair, Co-founder of
HealthUnity. “CerebraAI impressed our highly respected industry
judges then and continues to deliver on leading-edge technologies
being developed to help close the severe emergency care diagnostics
gap through its novel generative AI medical imaging approach.
Currently, 94% of emergency departments in the U.S. are capable of
drug intervention but only 20% of stroke victims receive treatment.
AI can change this.”
Known for fostering high-growth companies and her extensive
early stage venture capital experience, Shea Tate-Di Donna has
pioneered seven VC firms and is an accomplished entrepreneur,
fundraising strategist, and AI enthusiast. She was part of the
founding team at True Ventures and has held integral roles at
Pivotal Ventures, First Republic Bank, 1517 Fund, Mythos Ventures,
and multiple startups. Author of The Venture Fund Blueprint: How to
Access Capital, Achieve Launch, and Actualize Growth, she has
educated thousands of entrepreneurs and emerging fund managers
driving growth and innovation in the tech industry. With a rich
blend of industry insights and a robust deal network, Shea’s
strategic fundraising role on CerebraAI’s Advisory Board is set to
transform the company’s strategic vision into actionable results
for continued growth and lasting impact.
“I am committed to driving progressive change in the AI startup
sector and thrilled to be supporting the continued advancement of
CerebraAI’s transformative technology,” stated Shea Tate-Di Donna,
early stage AI venture expert and CerebraAI advisor. “With early
stage ventures, it is all about the people; I believe in Dos, his
team, and their commitment to utilizing AI for early stroke
detection and treatment. Their innovative approach has the
potential to revolutionize stroke care and save countless lives.
This is AI at its best, making a positive impact with a focus on
improved patient outcomes, and I am excited to support its
introduction to the investment community.”
“We are incredibly honored to welcome Shea Tate-Di Donna and Dr.
Jia Li as our newest members of the CerebraAI Advisory Board,”
stated Doszhan Zhussupov, CerebraAI Founder and CEO. “Jia is quite
the celebrity as an AI pioneer and highly respected industry leader
building and advising companies with award-winning platforms and
advancing trustworthy AI in healthcare. Shea’s extensive high-tech
venture experience and renowned work in transforming companies are
a testament to what she is bringing to CerebraAI through her
strategic excellence and thoughtful execution of each round. We are
extremely grateful to have their expertise and support.”
In addition to expert advisors supporting CerebraAI, the medical
imaging AI startup has received a warm welcome into multiple top
startup accelerators since relocating its headquarters from
Kazakhstan to the U.S. in February of 2024, including a recent
invitation to participate in MassChallenge’s 2024 U.S. Early Stage
Cohort after rigorous rounds of judging and being selected as part
of a standout group from more than 1,300 startup applications.
CerebraAI is also the first startup from Central Asia to be
accepted into the highly-vetted community of Stanford alumni and
professor founders at StartX and is honored to be a part of the
Microsoft for Startups Founders Hub, NVIDIA Inception Program,
MedTech Innovators, UC Berkeley’s Health Engine Accelerator, and
the vibrant community of Central Eurasia tech startups at the
Silkroad Innovation Hub in Silicon Valley.
About CerebraAI
Founded in 2018, CerebraAI is developing medical imaging
software for acute ischemic stroke detection through the power of
generative AI. Pioneering the development of a personalized
AI-generated digital twin of the patient’s pseudo-healthy brain
based on non-contrast CT (NCCT) scans, CerebraAI aims to leverage
its brain imaging algorithm to detect tissue abnormalities through
a detailed analysis map for accelerated diagnosis, triage, and
treatment of acute ischemic stroke victims. The software is being
designed for use on a mobile app or web-based platform. Currently
in use in 47 hospitals in Kazakhstan, two Uzbekistan hospitals, and
four hospitals in Saudi Arabia in pilot mode, with more than
150,000 patients analyzed, CerebraAI’s medical imaging software is
not yet approved in the U.S. The company recently relocated its
headquarters from Kazakhstan to Silicon Valley for this continued
U.S. product development, in addition to expansion plans in
multiple markets globally.
In 2022, StartUs Insights ranked CerebraAI’s deep learning model
among the top five global projects for diagnosing brain diseases
and the company has received global recognition, including Intel
Software’s AI Startup Olympics grand prize, Johnson & Johnson
Impact Ventures’ HealthTech Startups in APAC top award, EY’s Best
Innovative Startup honor, Medtronic’s Top 10 Most Innovative
Medical AI Startups in APAC in 2022, HealthUnity’s Generative AI
Startup Challenge Digital Health winner, the Digital Almaty Best
MedTech Award, Global Startup Awards’ Best VerTech Startup, the
Global Health Exhibition Innov8 Competition winner, the TechCrunch
Startup Battlefield 200 2023, and the LEAP 2024 Artificial
Intelligence Award. For more information, please visit
www.CerebraAI.ai and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723809704/en/
Laurie Peters CerebraAI 818 635-4101
Laurie.Peters@CerebraAI.ai